Claudin 18.2-a FAST-moving target in gastric cancer?

被引：21
|
作者：
Athauda, A.
Chau, I. [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 05期
关键词：
1ST-LINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; CAPECITABINE; ADENOCARCINOMA; EPIRUBICIN; ZOLBETUXIMAB; OXALIPLATIN; RILOTUMUMAB; CISPLATIN;
D O I：
10.1016/j.annonc.2021.02.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：584 / 586
页数：3
相关论文
共 50 条
  • [21] Angiogenesis in gastric cancer: hitting the target?
    Ilson, David H.
    LANCET, 2014, 383 (9911): : 4 - 6
  • [22] Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer
    Wu, Jian
    Chen, Jun
    Zhao, Yuetong
    Yuan, Mengyun
    Chen, Xu
    He, Xiangdong
    Zhang, Jun
    Shao, Guoqiang
    Sun, Qingmin
    MOLECULAR PHARMACEUTICS, 2024, 21 (07) : 3447 - 3458
  • [23] Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression
    Liu, Shengde
    Zhang, Zizhen
    Jiang, Lei
    Zhang, Miao
    Zhang, Cheng
    Shen, Lin
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [24] Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion
    Angerilli, Valentina
    Ghelardi, Filippo
    Nappo, Floriana
    Grillo, Federica
    Parente, Paola
    Lonardi, Sara
    Luchini, Claudio
    Pietrantonio, Filippo
    Ugolini, Clara
    Vanoli, Alessandro
    Fassan, Matteo
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 254
  • [25] Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials
    Kyuno, Daisuke
    Takasawa, Akira
    Takasawa, Kumi
    Ono, Yusuke
    Aoyama, Tomoyuki
    Magara, Kazufumi
    Nakamori, Yuna
    Takemasa, Ichiro
    Osanai, Makoto
    TISSUE BARRIERS, 2022, 10 (01):
  • [26] Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models
    Nishibata, Toshihide
    Weng, Jane
    Omori, Keisuke
    Sato, Yuji
    Nakazawa, Taisuke
    Suzuki, Tomoyuki
    Yamada, Tomohiro
    Nakajo, Ikumi
    Kinugasa, Fumitaka
    Tureci, Ozlem
    Sahin, Ugur
    Yoshida, Taku
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2024, 155 (03) : 84 - 93
  • [27] Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer
    Yin, Hongyan
    Luo, Rongkui
    Lv, Jing
    Mao, Wujian
    Shi, Hongcheng
    EUROPEAN RADIOLOGY, 2024,
  • [28] New therapeutic target molecules for gastric and gastroesophageal junction cancer
    Kawakami, Hisato
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (09) : 1228 - 1236
  • [29] Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression
    Kim, Hyung-Don
    Shin, Jinho
    Hyung, Jaewon
    Lee, Hyungeun
    Moon, Meesun
    Ma, Jeongeun
    Park, Young Soo
    Ryu, Min-Hee
    GASTRIC CANCER, 2025, 28 (01) : 74 - 82
  • [30] Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach
    Fassan, Matteo
    Kuwata, Takeshi
    Matkowskyj, Kristina A.
    Rocken, Christoph
    Ruschoff, Josef
    MODERN PATHOLOGY, 2024, 37 (11)
12345